Having completed an interrogation of studies examining PKC in the pathophysiology of diabetes, ischemia-reperfusion, and hypertension, we finish this review with a discussion of relevant clinical trials testing PKC inhibition in patients, and future avenues for investigation with an emphasis on clinical relevance. The gene discussed is PRRT2; the disease is diabetes mellitus.